Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
AffiliationObesity Research Group, and Dermatology Research Group, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
MetadataShow full item record
CitationGlucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. 2012: J Eur Acad Dermatol Venereol
JournalJournal of the European Academy of Dermatology and Venereology : JEADV
AbstractBackground Diabetes and obesity are more prevalent amongst psoriasis patients as is disturbance of the innate immune system. GLP-1 analogue therapy considerably improves weight and glycaemic control in people with type 2 diabetes and its receptor is present on innate immune cells. Objective We aimed to determine the effect of liraglutide, a GLP-1 analogue, on psoriasis severity. Methods Before and after 10 weeks of liraglutide therapy (1.2 mg subcutaneously daily) we determined the psoriasis area and severity index (PASI) and the dermatology life quality index (DLQI) in seven people with both psoriasis and diabetes (median age 48 years, median body mass index 48.2 kg/m(2) ). We also evaluated the immunomodulatory properties of liraglutide by measuring circulating lymphocyte subset numbers and monocyte cytokine production. Results Liraglutide therapy decreased the median PASI from 4.8 to 3.0 (P = 0.03) and the median DLQI from 6.0 to 2.0 (P = 0.03). Weight and glycaemic control improved significantly. Circulating invariant natural killer T (iNKT) cells increased from 0.13% of T lymphocytes to 0.40% (P = 0.03). Liraglutide therapy also effected a non-significant 54% decrease in the proportion of circulating monocytes that produced tumour necrosis factor alpha (P = 0.07). Conclusion GLP-1 analogue therapy improves psoriasis severity, increases circulating iNKT cell number and modulates monocyte cytokine secretion. These effects may result from improvements in weight and glycaemic control as well as from direct immune effects of GLP-1 receptor activation. Prospective controlled trials of GLP-1 therapies are warranted, across all weight groups, in psoriasis patients with and without type 2 diabetes.
- Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.
- Authors: Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, O'Reilly V, Lynch L, Doherty DG, Moynagh PN, Kirby B, O'Connell J, O'Shea D
- Issue date: 2011 Nov
- Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study.
- Authors: Buysschaert M, Baeck M, Preumont V, Marot L, Hendrickx E, Van Belle A, Dumoutier L
- Issue date: 2014 Jul
- Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide.
- Authors: Faurschou A, Knop FK, Thyssen JP, Zachariae C, Skov L, Vilsbøll T
- Issue date: 2014 Feb
- Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study.
- Authors: Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, Shao Z
- Issue date: 2019 Apr
- Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.
- Authors: Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T
- Issue date: 2015 Mar